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Hypercholesterolemia is a serious condition that may lead to coronary heart disease, heart attack and stroke raising 
the rate of morbidity and mortality in hypocholesterolemic patients. Statins are one of the largest selling drugs for 
hypercholesterolemia. They serve as potential competitive inhibitors of HMG-CoA reductase that catalyzes the rate-limiting 
step of cholesterol biosynthesis cascade. They can be broadly classified into fermentation-derived, semisynthetic and 
synthetic statins. For the current study, synthetic statins like fluvastatin, cerivastatin, rosuvastatin were subjected to in silico 
analysis for their competitive binding with HMG-CoA reductase through molecular docking. The molecular interaction 
between HMG-CoA reductase with statins and their ADMET properties were studied using Maestro suite of Schrödinger 
software. The results of molecular docking depicted that fluvastatin had the highest docking score while that of rosuvastatin 
was the least. The prediction of pharmacokinetics of drug performed by QikProp also pointed the efficacy of fluvastatin as a 
potent inhibitor for HMG-CoA reductase enabling it to be an effective drug to treat hypercholesterolemia among the three 
synthetic statins. 
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Hypercholesterolemia is a serious health condition 
that may lead to coronary heart disease, heart attack, 
stroke, and other complications, which raise the rate 
of morbidity and mortality in the hypocholesterolemic 
patients
1-3
. Our body can synthesize 50% or more of 
its own cholesterol requirement through mevalonate 
pathway and the remaining are obtained from our 
diet
4
. The conversion of 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) to mevalonate is the rate-limiting 




HMG-CoA reductase is a transmembrane protein, 
which contains eight domains that are anchored on the 
membrane of endoplasmic reticulum
5
. The active 
form of the enzyme has a tightly associated tetramer. 
The tetrameric structure of the enzyme consists of two 
catalytic sites formed by monomeric residues in a 
dimer
6
. Each monomer of HMG-CoA reductase has 
large and small domains. Both the domains are 
connected via a cis loop, which plays a key role in the 
formation of HMG-CoA binding site
7
. Recently, the 
regulation of HMG-CoA reductase received much 
attention that helps to modulate the mevalonate 
cascade. 
Statins are currently prescribed for hyper-
cholesterolemia which serves as effective competitive 
inhibitors of HMG-CoA reductase due to its structural 
similarity with HMG-CoA. Based on the routes of 
synthesis, these statins can broadly be classified into 
three major types, viz., fermentation derived, 
synthetic, and semi-synthetic statins. Lovastatin and 
compactin are fermentation derived statins whereas 
simvastatin is a semi-synthetic statin synthesized from 




A number of synthetic statins are available in the 
market, such as, cerivastatin, atorvastatin, fluvastatin, 
pitavastatin, and rosuvastatin, which are more 
efficient than the fermentation derived statins
10
. These 
statins are administrated orally, either in the form of 
hydroxy acid or lactone.  
In silico study is a convenient route to investigate 
those molecules which are difficult to isolate and 
purify from the fermentation broth. To the best of our 
knowledge, the molecular docking studies on 
synthetic statins with HMG-CoA reductase have not 









docking study that compares the affinity of different 
types of statins towards HMG-CoA reductase. Hence, 
the present study aims to consider important synthetic 
statins for the docking study. Also, it is a first attempt 
to compare the binding of HMG-CoA reductase  
with different statins in silico to understand types  
of interaction at the active site of the enzyme and  
to elucidate their structure-based functional 
relationship to develop a novel molecule for 
hypercholesterolemia. 
 
Materials and Methods 
Target Protein 
The crystal structure of the protein HMG- CoA 
reductase (PDB ID: 1HW8) was retrieved from RCSB 
Protein Data Bank. The protein structure was 
imported to Maestro software (Schrödinger, LLC, 
New York) for docking study. The docking studies  
of statins with HMG-CoA reductase requires  
the following sequence of steps that are shown  
in (Fig. 1). 
 
Preparation of HMG-CoA reductase 
Originally, the tetrameric protein consists of four 
monomeric sub-units (Fig. 2). The monomeric chain 
A and B to form a dimer. Similarly, chains C and D 
form another dimer, which are identical to each other. 
The dimeric form of HMG-CoA reductase was used 
for the docking studies, since, the functional form of 
HMG-CoA reductase is dimeric in nature
11,12
. 
Moreover, these dimers are symmetric in nature and 
are responsible for catalysis of the reaction as 
observed in original protein structure, where four 
monomeric subunits of compactin are composed to 
form a tetrameric protein. Each dimeric unit of the 
protein is bound with two ligands. 
The tetrameric protein was separated into its 
constituent chains (Chain A & B) and the dimeric unit 
as chain A was selected for further docking studies. 
To start docking of protein, it is essential to prepare 
the protein since the crystal structure obtained  
from Protein Data Bank consists of issues such as, 
improper bond orders, missing side chains, etc. 
Hence, the protein preparation process is much 
helpful in assigning proper bonds, bond order, 
addition of hydrogen, detection of disulphide bonds 
and correction of mislabelled elements. Further, the 
preparation of protein does not have any effect on the 
geometry of the protein; rather, it checks for any 
problem in the protein structure and correct those 
problems. The dimeric form of protein was prepared 
using protein preparation wizard in the Maestro suite 
of Schrödinger software for further process. 
 
Sitemap generation 
Sitemap tool of the Maestro helped in identification 
of active sites of a protein. In total four sitemaps were 
generated by the software for the protein. Similarly, 
sitemaps were generated for the dimeric form of the 
protein. The common sitemaps between the tetrameric 
and dimeric forms of the enzyme were selected for 
further processing and other site maps were discarded. 
Out of four sitemaps, two were found to be conserved 




Fig. 1 — Sequential steps involved in the docking study 
 
 
Fig. 2 — Tetrameric structure of HMG-CoA reductase 




Receptor grid generation 
The receptor grid is the three dimensional 
boundary for statins to bind with HMG-CoA 
reductase. The representation of shape and properties 
of the receptor on a grid provides a more accurate 
estimate of binding score for the different 
configurations of a ligand. The receptor grid for the 
protein was generated by specifying the active site 
residues using receptor grid generation panel in the 
glide application of Maestro. 
 
Ligand preparation 
A group of synthetic statins were employed for the 
current study as listed (Fig. 3) with their PubChem 
IDs in provided in (Table 1). The structures of statins 
were obtained from PubChem Compound database 
available at NCBI (www.ncbi.nlm.nih.gov) and were 
prepared for docking study using LigPrep application 
in Maestro software. The ligands employed for 
docking study should have three-dimensional 
configurations with realistic bond lengths and bond 
angles for obtaining the best results. The statins 
should not have any covalent bonds to the receptor of 
HMG-CoA reductase. Hence, LigPrep optimize the 
geometry of statins to check for any problems in the 
ligand structure and generates the structural variants. 
 
Molecular Docking using Glide 
Maestro software provides Glide tool for molecular 
docking studies to visualize and interpret the molecular 
level structural interaction between the target protein 
and ligand. Once the receptor grid is generated, the 
statins were docked with dimeric form of the protein. 
The Glide tool has generated different ligand 
conformations internally. However, a single best pose 
(confirmation) per ligand was represented as output 
based on the efficiency of binding. The efficiency of 
docking was evaluated using Glide (G) score. 
 
Prediction of ADMET Properties 
Hypercholesterolemia has been linked to 
cardiovascular disease, or to be specific to coronary 
heart disease. The main course of action of statins is 
reversible inhibition of hydroxymethylglutaryl 
coenzyme A (HMG-CoA) reductase. Statins may 
have a similar course of action but they greatly differ 
in terms of chemical structure and pharmacological 
attributes which in turn affect their clinical utilities 
and effectiveness. This difference between different 
statins and their attributes can be found from their 
ADMET profiles. ADMET is the abbreviation of 
pharmacokinetics properties of drugs (absorption, 
distribution, metabolism, excretion and toxicity) 
which is generally a pathway of how drug is 
distributed in the systemic circulation and how the 
metabolism takes place which is followed by flushing 
out of drug metabolite from the body. These studies 
are accompanied with toxicity analysis, which is also 
an important factor to understand any kind of toxicity 
associated with the drug molecule leading to certain 
harmful effects of drug. ADME analysis of synthetic 
statins was performed using QikProp tool 
(Schrödinger Inc.) and Toxicity analysis was done 
using PreADMET, which is a web based service for 
ADMET prediction. Statins are attributed to being  
the most effective and safe drug to control 
hypercholesterolemia. In current analysis, we studied 
 
 
Fig. 3 — Structures of Statins (A) Fluvastatin; (B) Cerivastatin; and (C) Rosuvastatin 
 
Table 1 — Docking scores of different statins 
S. No. Pubchem ID Statins Binding amino acid residues Docking score 
1. 446155 Fluvastatin Arg590, Glu559, Asn658 −7.161 
2. 446156 Cerivastatin Arg590, Asn658, Ser661, Lys691, Asn755 −5.705 
3. 446157 Rosuvastatin Arg590, Asn658, Glu665, His861 −5.688 




the following synthetic derivatives of statins namely 
fluvastatin, cerivastatin and rosuvastatin. 
 
Results 
Molecular docking studies of statins with HMG-CoA 
reductase 
Each statin (ligand) was prepared with possible 
three-dimensional orientation and hence they were 
docked separately with the enzyme. The docking score 
was considered as a parameter to indicate binding 
efficiency of statins with HMG-CoA reductase. The 
negative value of docking scores indicated better fitting 
of ligand into binding site of protein. The docking 
score for different statins was in the range of −7.161 to 
−5.688 (Table 1). Synthetic statins, such as, fluvastatin, 
cerivastatin and rosuvastatin were bound to HMG 
reductase with the docking scores of −7.161, −5.705 
and −5.688, respectively (Table 1).  
In addition to four hydrogen bonds and pi-cation 
interactions, fluvastatin formed a salt bridge with 
Arg 590, which was not observed with other statins  
(Fig. 4A). This could be the probable reason for  
its better docking score. It formed hydrogen bonds 
with the enzyme via amino acids i.e. Glu559, 
Arg590 and Asn658 and had an average bond  
length of 1.9651 Å. Cerivastatin interacted with a 
numbers of amino acids at the active site of  
the enzyme via both hydrogen and pi-cation bonds. 
It bound with Arg590, Asn658, Ser661 and Asn755 
(Fig. 4B) via hydrogen bonds with the mean  
bond length of 2.1377 Å. Interestingly, it has two  
pi-cation interactions with Arg590 and Lys691 of 
HMG-CoA reductase through the pyridine ring 
structure and fluorophenyl functional group of 
cerivastatin with a mean bond length of 2.137 Å 
(Table 2). Terminal carboxylic group of rosuvastatin 
formed hydrogen bonds with Arg590, Asn658, 
Glu665, and His861 (Fig. 4C) with the mean bond 
length of 2.044 Å.  
 
 
Fig. 4 — Ligand interaction diagram of HMG-CoA reductase with (A) Fluvastatin; (B) Cerivastatin; and (C) Rosuvastatin 





Absorption and Distribution Profiling 
QPlogS, the logarithm of aqueous solubility, is an 
important indicator of solubility of the drug. If the 
prediction of CIQPlogS is significantly different from 
QPlogS then the prediction indicates that solubility  
of drug is conformation dependent. The dipole 
moment/constant of a compound also influences the 
solubility of the compound. Dipole moment of drugs in 
current studies were found in approximation and are 
depicted in (Table 3). Assessment of cell permeability 
by QPPCaco and QPPMDCK data Cell lines for Caco-
2 and MDCK used as an in vitro model for the 
prediction of absorption of orally administered drugs 
in human small intestinal mucosa. Studies on Caco-2 
cell lines (at gut-blood barrier) can mimic various 
process of transport like, transcellular transport,  
para cellular transport, and some aspect of efflux and 
active transport. QikProp prediction is used to  
predict non-active transport of a drug in Caco-2 cell 
line. MDCK cell lines are used for prediction of 
absorption of a drug through blood-brain barrier 
(BBB). QikProp qualitatively predicted the oral 
absorption of the drug. 
 
Metabolism and Excretion 
Metabolism and excretion profiling was predicted 
to identify whether the drug during metabolism is  
an inhibitor or substrate of the biological enzymes 
(Table 4). 
Toxicity 
The toxicity analysis is a complex procedure, but 
there are some descriptors which can predict the 
toxicity of the compound to a good degree of 
accuracy. The main descriptors in Qikprop and 
PreADMET are QPloghERG, Ames test and Rodent 
Carcinogenicity. In QikProp analysis, QPloghERG  
is predicted by IC50 (Half maximal inhibitory 
concentration, is a measure of the potency of a 
substance in inhibiting a specific biological or 
biochemical function) value for the blockage of hERG 
K
+
 channels.  
Table 2 — Type of interactions between the active site of  
HMG-CoA reductase and statins 
Nature of amino acid Bond type Bond length (Å) 
Fluvastatin 
Arg590- Charged positive Salt bridge 4.9074 
Glu559- Charged negative H-bond (side chain) 1.9281 
Arg590- Charged positive H-bond (side chain) 2.0672 
Asn658- Polar H-bond (side chain) 1.9041 
Cerivastatin 
Arg590- Charged positive H-bond (side chain) 2.7620 
Arg590- Charged positive Pi-cation 4.2204 
Lys691- Charged positive Pi-cation 5.9371 
Asn658- Polar H-bond (side chain) 1.8452 
Ser661- Polar H-bond (side chain) 1.9135 
Asn755- Polar H-bond (side chain) 2.1415 
Rosuvastatin 
Arg590- Charged positive H-bond 1.8027 
Asn658- Polar H-bond 2.1233 
Glu665- Charged negative H-bond 2.0766 
His861- Polar H-bond 2.1966 
Table 3 — Comparative Absorption & Distribution  
Profiling of Statins 
Descriptors Fluvastatin Cerivastatin Rosuvastatin Range 
QPlogS 
(mol/dm3) 
−3.836 −5.252 −3.665 −6.5 - 0.5 
CIQPlogS 
(mol/dm3) 
−6.628 −6.382 −5.336 −6.5 - 0.5 
Dipole 
Moment 




130.112 107.539 17.484 > 500 – 
Great 





105.621 101.712 11.461 > 500 - 
Great 




82.792 80.608 64.587 25 - 80 




411.472 459.557 481.538 130 - 725 
QPloghERG −2.952 −2.97 −2.875 > −5 
 
 
Table 4 — Metabolism Profile 
 Names Fluvastatin Cerivastatin Rosuvastatin 
Metabolism      
 CYP2C19 
inhibition Inhibitor Inhibitor Non 
 CYP2C9 
inhibition Inhibitor Inhibitor Inhibitor 
 CYP2D6 
inhibition Non Non Non 
 CYP2D6 
substrate Non Non Non 
 CYP3A4 
inhibition Inhibitor Inhibitor Non 
 CYP3A4 
substrate Substrate Substrate Weakly 





Molecular docking is a technique which helps in 
identification of binding sites of ligand with the 
protein
18,19
. It is also used to find out potential ligands 
for a given target protein. In the current study, 
synthetic statins, namely, fluvastatin, cerivastatin, and 
rosuvastatin were used as ligands to study their 
interaction with HMG-CoA reductase. Some of the 
amino acids, such as, Arg590 and Asn658 were the 
conserved residues found at the active site of  
HMG-CoA reductase that interacted with most of the 
statins as observed from docking studies (Fig. 4). The 
guanidinium group of positively charged amino acid, 
Arg590, formed hydrogen bonds with the sulfone 
group of rosuvastatin and the terminal carboxylate 
group of HMG-CoA like moiety of statins, viz., 
cerivastatin and fluvastatin. The polar amino acid, 
Asn658, also formed hydrogen bonds with the 
hydroxy group of HMG like moiety of statins, such as 
cerivastatin, fluvastatin, and rosuvastatin. Lys691 is 
another common positively charged amino acid found 
at the cis loop of HMG-CoA reductase that formed  
pi-cation interaction with the fluorophenyl ring 
structure of cerivastatin. Other amino acids, such as 
Glu559, Ser661, Glu665, Asn755, and His861 were 
found at the active site of HMG-CoA reductase. 
Istvan and Deisenhofer (2001) observed that the 
following amino acids, serine (Ser648), lysine 
(Lys691 and 692), and aspartate (Asp690) at the  
cis-loop of HMG-CoA reductase interacted with 
HMG-CoA-like moieties of statins through polar 
interactions. Carbonell and Freire (2005) reported that 
the sulfonyl group in rosuvastatin formed hydrogen 
bonds with the hydroxyl group of Ser565
11
. These 
results, to some extent, ascertained the accuracy of the 
prediction of the active site and docking results of the 
present work. Some hydrophobic amino acids are 
found at the active site of the enzyme and they could 
play a key role in bringing those statins towards the 
active site of the enzyme by hydrophobic interactions. 
Tabernero et al. (2003) reported the importance of 
HMG-CoA like moiety of statins in binding with 
HMG-CoA reductase. Moreover, they have also 
reported crucial role of hydrophobic interaction 
between active site of the enzyme and the 
hydrophobic regions (decalin ring and butyryl side 
chain) of statins. The simple sulfonamide structure in 
rosuvastatin formed a hydrogen bond with positively 
charged amino acids via a carbonyl group. It showed 
that the carbonyl group present at HMG-CoA like 
moiety and sulfonyl group are found to be crucial in 
the binding of statins
20
.  
Overall, the present study showed the importance 
of functional groups, such as HMG-CoA like moiety 
and high electron density chains, such as, sulfone 
group, fluorophenyl group, and pi-conjugated ring 
structures, to develop next generation statins 
molecules with improved efficiency. 
Hypercholesterolemia has been linked to 
cardiovascular disease or coronary heart disease. The 
main course of action of statins is reversible inhibition 
of hydroxymethylglutaryl coenzyme A (HMG-CoA) 
reductase. Synthetic statins may have a similar course 
of action but they greatly differ in terms of a chemical 
structure and pharmacological attributes which in turn 
affect their clinical utilities and effectiveness. This 
difference between different statins and their 
attributes can be found from their ADMET profiles. 
The solubility of any drug can either be 
conformation-dependent or conformation independent 
which is determined by the difference in values of 
QPlogS and CIQPlogS. Fluvastatin exhibited a 
significant difference in values of QPlogS and 
CIQPlogS (2.792) compared to cerivastatin, and 
rosuvastatin and hence it can be concluded that the 
solubility of fluvastatin was dependent on its 
conformation. The dipole of fluvastatin, cerivastatin 
and rosuvastatin was 5.331, 2.896, and 5.764, 
respectively. These values are within the range of  
1.0−12.5 which is recommended for a molecule to act 
as a suitable drug. High dipole value means that the 
molecule is highly soluble in an aqueous medium and 
hence they are less likely to be administered orally. 
From the results of dipole, it can be inferred that 
rosuvastatin is highly soluble among the three 
synthetic statins. QPPCaco and QPPMDCK are 
parameters that determine the permeability of a likely 
drug across the gut-blood barrier and blood-brain 
barrier, respectively. From Table 3 it can be seen that 
fluvastatin has the highest permeability in Caco and 
MDCK cells among the three synthetic statins 
whereas rosuvastatin has very poor permeability. The 
percentage of human oral absorption is high for 
fluvastatin (82.792%) and least for rosuvastatin 
(64.587). This can be correlated with the value of 
dipole for the synthetic statins. 
Binding to human serum albumin (HSA) 
determined the distribution of drugs inside the body. 
This also helps in solubilisation and uniform 
distribution of the drug in tissues. From the data of 




QPlogHSA, it can be predicted that fluvastatin has the 
highest binding to HAS than cerivastatin and 
rosuvastatin. The IC50 value of any drug is predicted by 
its efficiency to block HERG K
+
 channels. From Table 3, 
it can be observed that there is no significant difference 
between the QPlogHERG values of fluvastatin and 
cerivastatin whereas that of rosuvastatin is least.  
The metabolic profile of the three statins showed that 
instead of having comparatively lower inhibitory 
activity, rosuvastatin has shown the least interference as 
non-inhibitor and weak substrate for metabolic enzymes. 
Hence it is less likely to have side effects. The toxicity 
study for all three compounds is found to be negative for 
most of the descriptors and risk factors are also found in 
approximation for all the drugs. Results for fluvastatin 
are found with high risk for hERG inhibition hence the 
study confined the drugs with potential inhibitory effect 
for HMG-CoA but can have certain to side effects as per 
toxicity profiling (Table 5). 
The results of molecular docking and 
pharmacokinetics profiles of three synthetic statins  
with HMG-CoA reductase indicate that fluvastatin  
binds strongly with amino acids at the active site of 
HMG-CoA. The absorption profile considered that 
fluvastatin is better absorbed compared to the remaining 
two statins. But it might have certain side effects as 
pointed out by the metabolism and toxicity profile of 
fluvastatin. On the other hand, rosuvastatin has shown 
the least risk of side effects with poor interactions with 
HMG-CoA reductase. The development of suitable 
analogues of rosuvastatin which have better interactions 
with HMG-CoA reductase can be a suitable option for 




Hypercholesterolemia has been linked to 
cardiovascular disease or coronary heart disease. 
Statins, potential inhibitors of HMG-CoA reductase, 
can be explored as suitable drug candidates for 
treatment of hypercholesterolemia. In the current work, 
synthetic statins, namely, fluvastatin, cerivastatin  
and rosuvastatin were studied for their interaction  
with HMG-CoA reductase. The three-dimensional 
molecular interactions between statins and HMG-CoA 
reductase were mimicked using Schrödinger software 
to understand the structural based functionality of 
statins and molecular mechanism of interactions at the 
active site of the enzyme. From molecular docking 
interactions and ADME predictions it can be concluded 
that fluvastatin is the most suitable drug among  
the three synthetic statins whereas rosuvastatin is  
found with comparatively weaker interaction and 
pharmacokinetics. This kind of studies with the help of 
computer-aided drug discovery tools help in the 
identification of target-ligand interaction at the 
molecular level, hence give a deeper insight for further 
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